Canadian Bioceutical reports revenue up 14%

The Canadian Bioceutical Corporation (CSE:BCC) (OTC:CBICF), the Toronto-based operator of cannabis facilities, primarily operating in the USA, reported financial results for the first quarter of its 2018 fiscal year, ending June 30, 2017.

Revenue was up 14% from the past quarter to $5.1 million, EBITDA climbed into positive territory, and its bottom line Net Loss dropped significantly from $3.8 million the previous quarter to $800,000. Most of BCC’s operations were acquired in 2017, so full year reporting was not considered as relevant as reporting versus last quarter’s results.

BCC stock traded up 5% to $0.345 on the news.

Scott Boyes, the CEO of BCC, said that the company is on top of its aggressive growth strategy. They are currently developing a dispensary in Nevada, to be operational by November 2017, and three in Massachusetts, where they expect to begin cultivation in spring of 2018.

BCC’s goal is to operate 10 dispensaries in 4 states, producing 9 million grams per year and 1.2 million grams in concentrates. From this base, they expect to generate strong returns, and will then be able to expand more, both from internal and external capital.

BCC has a partnership with MJardin to supply cultivation services to certain BCC operations, first in Nevada. They also have a partnership with Panaxia, an Israeli pharma company, to provide smokeless pharma-grade products that are not readily available in the US.

Source Canadian Bioceutical Corporation press release

Canadian Bioceutical reports revenue up 14%

About Cannin.com: Your Marijuana Stocks Resource

Cannin is your #1 resource for marijuana stocks. Our global team of experts evaluates all emerging marijuana stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best marijuana stock investments for 2020.

Use Cannin as your resource for:

Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.

Many market analysts expect the legal marijuana industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in marijuana stocks is now.

Are you interested in marijuana stocks like Curaleaf, Trulieve, Aurora Cannabis, or Charlotte’s Web,?

Are you looking to buy stock in marijuana companies for 2020? Interested in emerging penny marijuana stocks? Looking for the best Canadian marijuana stocks to invest in? We can help.

Predict price movements of marijuana stocks several hours in advance with our proprietary algorithmic stock trading software.

+25% Gains in 2020
+49.8% Gains in 2019
108% Backtested since 2012

We’re so confident you’ll love our algotrading marijuana stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best marijuana stocks – we’ll show you how at cannin.com.

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Best Hemp Stocks 2020

Canadian Bioceutical reports revenue up 14%